• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Daxor’s Share Price Spikes 83 Percent with Academic Publication

    Gabrielle Lakusta
    Oct. 30, 2018 03:45PM PST
    Medical Device Investing
    NYSE:DXR

    The controlled study, published in The Journal of the American College of Cardiology, shows a reduction in deaths and hospital readmissions.

    Daxor (NYSE:DXR) has driven investor interest with data published in an academic journal for its medical device in an announcement on Tuesday (October 30). The company’s share price increased over 83 percent on Tuesday to close at US$8.80.

    All patients in the study received personalized treatment for acute heart failure with Daxor’s blood volume analyzer device, the BVA-100. The controlled study, published in “The Journal of the American College of Cardiology,” based its research on a reduction of deaths and hospital readmissions.

    Mortality rates were reduced by 82 percent while hospital readmission rates reduced by 56 percent 30 days after treatment. These results suggest Daxor’s technology has successfully intervened on a high unmet need for these patients.

    “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition,” Michael Feldschuh, CEO of Daxor, said in the press release.

    The device works by taking blood samples from the patient, which is mixed with tracer substance and is compared with other indicators. It is used in conjunction with a patented single-use injection kit.

    Patients in the trial had volumes of blood, red blood cell and plasma measured from Daxor’s device. Patients were given a decongestion and treatment strategy from the measurement given.

    Additional results from the study include one-year death rates lowered to 4.9 percent compared to 35.5 percent for the BVA-100 and the propensity score control, respectively. The score was developed from the Centers for Medicare & Medicaid Service (CMS) data for demographics, comorbidity and time of treatment.

    The 30-day hospital readmission rate demonstrated less heart failure and cardiac non-heart failure readmissions. Both rates improved from the propensity score control by over 50 percent.

    “These results clearly show that BVA measurement has a one-to-one relationship in achieving meaningful improvements,” John Strobeck, one of the study’s lead authors, said.

    The BVA-100 shows results within an hour, but in emergency situations doctors can see preliminary results in 30 minutes. Previous devices used to measure the blood volume took four to six hours to perform, and was difficult to do so.

    Feldschuh added heart failure is one of the largest areas of healthcare spending, and one of the most significant treatment challenges for about six million US patients. He added this amount is expected to double as the growing population ages.

    Blood volume tests can identify the best treatment for multiple serious conditions dealing with blood and cardiac diseases. Other indications for the test include: hypertension, syncope, red cell mass and acute blood loss during surgery or accidents among many others.

    This is Daxor’s only commercialized product and has been used in over 40,000 cases and many research studies. It’s the only US Food and Drug Administration (FDA)-approved product for rapid direct blood volume measurement. The company’s focus is to continue advancing technologies to improve patient care, and hospital and physician abilities.

    No milestones have been announced just yet, but investors can look to the company’s website for updates on this device and other studies.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

    nyse:dxrblood volume analyzermedical device investingjournal of the american college of cardiology
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Cardiex Limited (ASX:CDX)

    Cardiex Limited

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU

    Cleo Diagnostics

    COV:AU

    Ocumetics Technology

    OTC:CA

    Premier Health of America

    PHA:CA

    Bloom Health Partners

    BLMH:CNX

    Applied UV

    AUVI:NSD
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×